Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

841 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Allogeneic BCMA-targeting CAR T cells in relapsed/refractory multiple myeloma: phase 1 UNIVERSAL trial interim results.
Mailankody S, Matous JV, Chhabra S, Liedtke M, Sidana S, Oluwole OO, Malik S, Nath R, Anwer F, Cruz JC, Htut M, Karski EE, Lovelace W, Dillon M, Butz E, Ying W, Balakumaran A, Kumar SK. Mailankody S, et al. Among authors: kumar sk. Nat Med. 2023 Feb;29(2):422-429. doi: 10.1038/s41591-022-02182-7. Epub 2023 Jan 23. Nat Med. 2023. PMID: 36690811 Clinical Trial.
Randomized phase 2 trial of ixazomib and dexamethasone in relapsed multiple myeloma not refractory to bortezomib.
Kumar SK, LaPlant BR, Reeder CB, Roy V, Halvorson AE, Buadi F, Gertz MA, Bergsagel PL, Dispenzieri A, Thompson MA, Crawley J, Kapoor P, Mikhael J, Stewart K, Hayman SR, Hwa YL, Gonsalves W, Witzig TE, Ailawadhi S, Dingli D, Go RS, Lin Y, Rivera CE, Rajkumar SV, Lacy MQ. Kumar SK, et al. Blood. 2016 Nov 17;128(20):2415-2422. doi: 10.1182/blood-2016-05-717769. Epub 2016 Oct 4. Blood. 2016. PMID: 27702799 Free PMC article. Clinical Trial.
IAP antagonists induce anti-tumor immunity in multiple myeloma.
Chesi M, Mirza NN, Garbitt VM, Sharik ME, Dueck AC, Asmann YW, Akhmetzyanova I, Kosiorek HE, Calcinotto A, Riggs DL, Keane N, Ahmann GJ, Morrison KM, Fonseca R, Lacy MQ, Dingli D, Kumar SK, Ailawadhi S, Dispenzieri A, Buadi F, Gertz MA, Reeder CB, Lin Y, Chanan-Khan AA, Stewart AK, Fooksman D, Bergsagel PL. Chesi M, et al. Among authors: kumar sk. Nat Med. 2016 Dec;22(12):1411-1420. doi: 10.1038/nm.4229. Epub 2016 Nov 14. Nat Med. 2016. PMID: 27841872 Free PMC article. Clinical Trial.
Treatment patterns and outcome following initial relapse or refractory disease in patients with systemic light chain amyloidosis.
Tandon N, Sidana S, Gertz MA, Dispenzieri A, Lacy MQ, Buadi FK, Dingli D, Fonder AL, Hobbs MA, Hayman SR, Gonsalves WI, Hwa YL, Kapoor P, Kyle RA, Leung N, Go RS, Lust JA, Russell SJ, Zeldenrust SR, Rajkumar SV, Kumar SK. Tandon N, et al. Among authors: kumar sk. Am J Hematol. 2017 Jun;92(6):549-554. doi: 10.1002/ajh.24723. Epub 2017 Apr 26. Am J Hematol. 2017. PMID: 28314084 Free article.
Predictors of early treatment failure following initial therapy for systemic immunoglobulin light-chain amyloidosis.
Tandon N, Sidana S, Rajkumar SV, Dispenzieri A, Gertz MA, Lacy MQ, Kyle RA, Buadi FK, Dingli D, Hayman SR, Fonder AL, Hobbs MA, Gonsalves WI, Kapoor P, Hwa YL, Leung N, Go RS, Lust JA, Russell SJ, Zeldenrust SR, Kumar SK. Tandon N, et al. Among authors: kumar sk. Amyloid. 2017 Sep;24(3):183-188. doi: 10.1080/13506129.2017.1351354. Epub 2017 Jul 12. Amyloid. 2017. PMID: 28699793
Impact of involved free light chain (FLC) levels in patients achieving normal FLC ratio after initial therapy in light chain amyloidosis (AL).
Tandon N, Sidana S, Dispenzieri A, Gertz MA, Lacy MQ, Dingli D, Buadi FK, Fonder AL, Hayman SR, Hwa YL, Hobbs MA, Kapoor P, Gonsalves WI, Leung N, Go RS, Lust JA, Russell SJ, Kyle RA, Rajkumar SV, Kumar SK. Tandon N, et al. Among authors: kumar sk. Am J Hematol. 2018 Jan;93(1):17-22. doi: 10.1002/ajh.24919. Epub 2017 Oct 20. Am J Hematol. 2018. PMID: 28960427 Free article.
Prognostic significance of circulating plasma cells by multi-parametric flow cytometry in light chain amyloidosis.
Sidana S, Tandon N, Dispenzieri A, Gertz MA, Dingli D, Jevremovic D, Morice WG, Kapoor P, Kourelis TV, Lacy MQ, Hayman SR, Buadi FK, Leung N, Go RS, Lin Y, Russell SJ, Lust JA, Zeldenrust SR, Warsame R, Hwa YL, Hobbs M, Fonder A, Kyle RA, Rajkumar SV, Kumar SK, Gonsalves WI. Sidana S, et al. Among authors: kumar sk. Leukemia. 2018 Jun;32(6):1421-1426. doi: 10.1038/s41375-018-0063-7. Epub 2018 Feb 21. Leukemia. 2018. PMID: 29483709 Free PMC article.
Relapse after complete response in newly diagnosed multiple myeloma: implications of duration of response and patterns of relapse.
Sidana S, Tandon N, Dispenzieri A, Gertz MA, Buadi FK, Lacy MQ, Dingli D, Fonder AL, Hayman SR, Hobbs MA, Gonsalves WI, Warsame RM, Kourelis T, Hwa YL, Kapoor P, Kyle RA, Leung N, Go RS, Rajkumar SV, Kumar SK. Sidana S, et al. Among authors: kumar sk. Leukemia. 2019 Mar;33(3):730-738. doi: 10.1038/s41375-018-0271-1. Epub 2018 Oct 15. Leukemia. 2019. PMID: 30323358
841 results